Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 1c

February 10, 2021 4:27 PM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.15, $0.01 better than the analyst estimate of $0.14. Revenue for the quarter came in at $67.65 million versus the consensus estimate of $64 million.

"I am very proud of the significant accomplishments we realized during this challenging year," said Mihael H. Polymeropoulos, M.D., President and CEO of Vanda. "As we look forward to the new year, it is worth noting some of our significant accomplishments from 2020: Vanda achieved record commercial revenue despite extraordinary difficulty in the field, which we believe is a testament to the value our products bring to patients; HETLIOZĀ® received FDA approval for nighttime sleep disturbances in patients with Smith-Magenis Syndrome; our tradipitant gastroparesis Phase III study continued recruitment; the FDA approved individual Expanded Access to tradipitant for multiple gastroparesis patients; we launched the tradipitant study for COVID-19 pneumonia; the FDA approved the Investigational New Drug application for VSJ-110 in allergic conjunctivitis; the United States Supreme Court affirmed the patent ruling on FanaptĀ®; and our research and development efforts advanced the clinical programs for our commercial assets as well as those in our pipeline. We look forward to another great year of accomplishments, including further revenue growth, the commercial launch of HETLIOZĀ® in patients with Smith-Magenis Syndrome, and the results of the tradipitant Phase III study in gastroparesis, to highlight a few."

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

Earnings, FDA